• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    US Conjugate Vaccine Market

    ID: MRFR/Pharma/11305-CR
    100 Pages
    Garvit Vyas
    December 2023

    US Conjugate Vaccines Market Research Report, By Type (Haemophilus B, Monovalent, Multivalent, And Others), Indication (Influenza, Pneumococcal, Meningococcal, And Others), End Users (Pediatrics And Adults) - Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US Conjugate Vaccine Market Infographic
    Purchase Options

    US Conjugate Vaccine Market Summary

    The US Conjugate Vaccine market is projected to grow from 8.5 USD Billion in 2024 to 15.2 USD Billion by 2035, reflecting a robust growth trajectory.

    Key Market Trends & Highlights

    US Conjugate Vaccine Key Trends and Highlights

    • The market is expected to expand at a compound annual growth rate (CAGR) of 5.43% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 15.2 USD Billion, indicating a substantial increase from the base year.
    • In 2024, the market is valued at 8.5 USD Billion, showcasing the current scale of the US Conjugate Vaccine sector.
    • Growing adoption of conjugate vaccines due to increasing awareness of vaccine-preventable diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 8.5 (USD Billion)
    2035 Market Size 15.2 (USD Billion)
    CAGR (2025 - 2035) 5.43%

    Major Players

    Apple Inc (US), Microsoft Corp (US), Amazon.com Inc (US), Alphabet Inc (US), Berkshire Hathaway Inc (US), Meta Platforms Inc (US), Tesla Inc (US), Johnson & Johnson (US), Visa Inc (US), Procter & Gamble Co (US)

    Key Companies in the US Conjugate Vaccine Market market include

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 NA (USD Billion)
    Market Size 2024 NA (USD Billion)
    Market Size 2032 NA (USD Billion)
    Compound Annual Growth Rate (CAGR) NA % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered   North America, Europe, Asia Pacific, and Rest of the World
      Key Vendors   Pfizer Inc (US), Novartis AG (Switzerland), Sanofi S.A.(France), Serum Institute of India Pvt. Ltd (India), GlaxoSmithKline plc (UK), Merck & Co., Inc (US), Incepta Pharmaceuticals Ltd (Bangladesh), BIO-MED (US), Walvax Biotechnology Co., Ltd (China), Bio-Manguinhos (Brazil)
      Key Market Opportunities   Increasing inclusion in national immunization programs
      Key Market Drivers   Increasing awareness and surge in travel vaccine Increase in R&D for vaccine technology

    FAQs

    What is the current market size of the US Conjugate Vaccine Market in 2024?

    The US Conjugate Vaccine Market is expected to be valued at 13.63 billion USD in 2024.

    What is the projected market size of the US Conjugate Vaccine Market by 2035?

    By 2035, the US Conjugate Vaccine Market is projected to reach 21.05 billion USD.

    What is the expected compound annual growth rate (CAGR) for the US Conjugate Vaccine Market between 2025 and 2035?

    The expected CAGR for the US Conjugate Vaccine Market from 2025 to 2035 is 4.027%.

    Which segment of the market is likely to have the largest share in 2024?

    In 2024, Pneumococcal Conjugate Vaccines are expected to hold the largest market share, valued at 5.24 billion USD.

    How much is the Meningococcal Conjugate Vaccines segment valued at in 2024?

    The Meningococcal Conjugate Vaccines segment is valued at 3.44 billion USD in 2024.

    Who are the major players in the US Conjugate Vaccine Market?

    Major players in the market include Vaxart, Bristol Myers Squibb, Novartis, AstraZeneca, and Merck.

    What are the expected market values for Haemophilus Influenzae Type B and Typhoid Conjugate Vaccines in 2024?

    Haemophilus Influenzae Type B Conjugate Vaccines are valued at 2.35 billion USD, while Typhoid Conjugate Vaccines are valued at 2.6 billion USD in 2024.

    What are some key growth drivers for the US Conjugate Vaccine Market?

    Key growth drivers include rising healthcare awareness and increasing vaccine coverage among populations.

    What challenges might the US Conjugate Vaccine Market face in the coming years?

    Challenges may include competition from alternative vaccine technologies and regulatory hurdles.

    What opportunities exist for growth within the US Conjugate Vaccine Market?

    Opportunities for growth include advancements in vaccine technology and expanding vaccination programs.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials